Natera (NASDAQ:NTRA – Get Rating) had its price target upped by investment analysts at Piper Sandler from $60.00 to $70.00 in a research note issued on Wednesday, The Fly reports. The firm presently has an "overweight" rating on the medical research company's stock. Piper Sandler's target price points to a potential upside of 34.54% from the company's current price.

A number of other equities analysts have also recently commented on NTRA. BTIG Research lifted their target price on shares of Natera to $95.00 in a report on Monday. JPMorgan Chase & Co. lifted their target price on shares of Natera from $80.00 to $100.00 in a report on Friday, August 5th. Cowen cut their target price on shares of Natera from $110.00 to $100.00 in a report on Friday, May 6th. Stephens assumed coverage on shares of Natera in a report on Monday, April 25th. They issued an "overweight" rating and a $54.00 target price on the stock. Finally, Robert W. Baird lowered their price objective on shares of Natera from $100.00 to $71.00 in a research report on Friday, May 6th. One equities research analyst has rated the stock with a sell rating and seven have given a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $93.64.

Natera Stock Down 1.0 %

NTRA stock opened at $52.03 on Wednesday. The company has a current ratio of 3.58, a quick ratio of 3.46 and a debt-to-equity ratio of 0.63. Natera has a twelve month low of $26.10 and a twelve month high of $129.09. The company's 50 day moving average is $43.17 and its two-hundred day moving average is $44.79. The stock has a market cap of $5.04 billion, a P/E ratio of -8.59 and a beta of 1.33.

Insiders Place Their Bets

In other Natera news, CEO Steven Leonard Chapman sold 1,652 shares of the business's stock in a transaction on Thursday, June 23rd. The shares were sold at an average price of $35.76, for a total transaction of $59,075.52. Following the sale, the chief executive officer now directly owns 64,777 shares in the company, valued at approximately $2,316,425.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Natera news, CEO Steven Leonard Chapman sold 1,652 shares of the business's stock in a transaction on Thursday, June 23rd. The shares were sold at an average price of $35.76, for a total transaction of $59,075.52. Following the sale, the chief executive officer now directly owns 64,777 shares in the company, valued at approximately $2,316,425.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Robert Alan Schueren sold 1,390 shares of the business's stock in a transaction on Tuesday, June 28th. The stock was sold at an average price of $39.02, for a total transaction of $54,237.80. Following the sale, the chief operating officer now owns 1,360 shares in the company, valued at $53,067.20. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 13,966 shares of company stock worth $550,755. Corporate insiders own 10.27% of the company's stock.

Institutional Investors Weigh In On Natera

Several institutional investors and hedge funds have recently made changes to their positions in NTRA. Ronald Blue Trust Inc. purchased a new stake in shares of Natera in the 2nd quarter worth about $26,000. CENTRAL TRUST Co boosted its position in shares of Natera by 200.0% in the 4th quarter. CENTRAL TRUST Co now owns 300 shares of the medical research company's stock worth $28,000 after buying an additional 200 shares in the last quarter. CWM LLC boosted its position in shares of Natera by 1,041.0% in the 1st quarter. CWM LLC now owns 696 shares of the medical research company's stock worth $28,000 after buying an additional 635 shares in the last quarter. Parallel Advisors LLC boosted its position in shares of Natera by 84.2% in the 2nd quarter. Parallel Advisors LLC now owns 829 shares of the medical research company's stock worth $29,000 after buying an additional 379 shares in the last quarter. Finally, Industrial Alliance Investment Management Inc. purchased a new stake in shares of Natera in the 4th quarter worth about $30,000. 96.24% of the stock is currently owned by hedge funds and other institutional investors.

About Natera

(Get Rating)

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

Recommended Stories

• Get a free copy of the StockNews.com research report on Natera (NTRA)
• Is Sanofi A Buy, Despite Recent Stumbles?
• If You Hate Speed Cameras, Then You'll Like Verra Mobility Stock
• Institutional Support For TJX Companies May Cap Gains
• Starbucks Stock, Is Brand Loyalty Enough Reason to Buy
• BJ's Wholesale Club Pops, Will Costco Be Next?

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.